Farringdon Capital’s Boston Scientific BSX Stock Holding History

Farringdon Capital’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-38,104	Closed	-$2.39M	–	226
2026 Q1	$2.39M	Buy	+38,104	New	+$3.05M	0.52%	52
2025 Q4	–	Sell	-22,570	Closed	-$2.2M	–	460
2025 Q3	$2.2M	Buy	+22,570	New	+$2.34M	0.56%	31
2025 Q2	–	Sell	-2,086	Closed	-$210K	–	445
2025 Q1	$210K	Buy	+2,086	New	+$210K	0.11%	280

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Farringdon Capital's BSX Position: Q2 2026 in Review

Farringdon Capital sold out of Boston Scientific (BSX) in Q2 2026, closing a stake of 38,104 shares — an estimated $2.39M sold.

Farringdon Capital first reported a position in BSX in Q1 2025 and held it in 3 quarters. The position peaked at $2.39M in Q1 2026. 1,477 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

Farringdon Capital reported no remaining Boston Scientific position as of Q2 2026 after selling out during the quarter.
Farringdon Capital sold 38,104 Boston Scientific shares in Q2 2026, an estimated $2.39M.
Farringdon Capital first reported a position in Boston Scientific in Q1 2025 and held it in 3 quarters.
Farringdon Capital's Boston Scientific position peaked at $2.39M in Q1 2026.
1,477 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Farringdon Capital's 13F filing for Q2 2026, filed 12 Aug 2026.